Effects of repeated adolescent exposure to cannabis smoke on cognitive outcomes in adulthood.
Cannabis
anxiety
executive function
marijuana
smoke
working memory
Journal
Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
pubmed:
10
12
2020
medline:
27
1
2022
entrez:
9
12
2020
Statut:
ppublish
Résumé
Cannabis (marijuana) is the most widely used illicit drug in the USA, and consumption among adolescents is rising. Some animal studies show that adolescent exposure to delta 9-tetrahydrocannabinol or synthetic cannabinoid receptor 1 agonists causes alterations in affect and cognition that can persist into adulthood. It is less clear, however, whether similar alterations result from exposure to cannabis via smoke inhalation, which remains the most frequent route of administration in humans. To begin to address these questions, a rat model was used to determine how cannabis smoke exposure during adolescence affects behavioral and cognitive outcomes in adulthood. Adolescent male Long-Evans rats were assigned to clean air, placebo smoke, or cannabis smoke groups. Clean air or smoke exposure sessions were conducted daily during adolescence (from P29-P49 days of age ) for a total of 21 days, and behavioral testing began on P70. Compared to clean air and placebo smoke conditions, cannabis smoke significantly attenuated the normal developmental increase in body weight, but had no effects on several measures of either affect/motivation (open field activity, elevated plus maze, instrumental responding under a progressive ratio schedule of reinforcement) or cognition (set shifting, reversal learning, intertemporal choice). Surprisingly, however, in comparison to clean air controls rats exposed to either cannabis or placebo smoke in adolescence exhibited enhanced performance on a delayed response working memory task. These findings are consistent with a growing body of evidence for limited long-term adverse cognitive and affective consequences of adolescent exposure to relatively low levels of cannabinoids.
Sections du résumé
BACKGROUND
BACKGROUND
Cannabis (marijuana) is the most widely used illicit drug in the USA, and consumption among adolescents is rising. Some animal studies show that adolescent exposure to delta 9-tetrahydrocannabinol or synthetic cannabinoid receptor 1 agonists causes alterations in affect and cognition that can persist into adulthood. It is less clear, however, whether similar alterations result from exposure to cannabis via smoke inhalation, which remains the most frequent route of administration in humans.
AIMS
OBJECTIVE
To begin to address these questions, a rat model was used to determine how cannabis smoke exposure during adolescence affects behavioral and cognitive outcomes in adulthood.
METHODS
METHODS
Adolescent male Long-Evans rats were assigned to clean air, placebo smoke, or cannabis smoke groups. Clean air or smoke exposure sessions were conducted daily during adolescence (from P29-P49 days of age ) for a total of 21 days, and behavioral testing began on P70.
RESULTS
RESULTS
Compared to clean air and placebo smoke conditions, cannabis smoke significantly attenuated the normal developmental increase in body weight, but had no effects on several measures of either affect/motivation (open field activity, elevated plus maze, instrumental responding under a progressive ratio schedule of reinforcement) or cognition (set shifting, reversal learning, intertemporal choice). Surprisingly, however, in comparison to clean air controls rats exposed to either cannabis or placebo smoke in adolescence exhibited enhanced performance on a delayed response working memory task.
CONCLUSIONS
CONCLUSIONS
These findings are consistent with a growing body of evidence for limited long-term adverse cognitive and affective consequences of adolescent exposure to relatively low levels of cannabinoids.
Identifiants
pubmed: 33295231
doi: 10.1177/0269881120965931
pmc: PMC8187454
mid: NIHMS1668895
doi:
Substances chimiques
Smoke
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
848-863Subventions
Organisme : NIDA NIH HHS
ID : R21 DA039349
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD071866
Pays : United States
Références
J Psychopharmacol. 2013 Jan;27(1):19-27
pubmed: 23042808
J Anal Toxicol. 2015 Oct;39(8):580-7
pubmed: 26378131
Psychopharmacology (Berl). 1996 Nov;128(2):161-70
pubmed: 8956377
J Psychopharmacol. 2010 Nov;24(11):1659-69
pubmed: 19525335
Neuropsychopharmacology. 2019 Jul;44(8):1406-1414
pubmed: 30965351
Psychopharmacology (Berl). 1999 Jan;141(1):99-106
pubmed: 9952071
Neuropsychopharmacology. 2003 Jul;28(7):1356-65
pubmed: 12784123
Braz J Psychiatry. 2010 May;32 Suppl 1:S31-40
pubmed: 20512268
Am J Cardiol. 2006 Aug 15;98(4):478-84
pubmed: 16893701
Drug Alcohol Depend. 2011 Jul 1;116(1-3):86-92
pubmed: 21227600
Psychopharmacology (Berl). 2012 Dec;224(4):489-99
pubmed: 22760484
J Psychopharmacol. 2004 Dec;18(4):502-8
pubmed: 15582916
Br J Psychiatry. 2002 Mar;180:216-21
pubmed: 11872513
Int J Neuropsychopharmacol. 2012 Oct;15(9):1251-64
pubmed: 22243563
PLoS One. 2011;6(10):e25856
pubmed: 22016780
Neurotoxicol Teratol. 2005 Mar-Apr;27(2):231-9
pubmed: 15734274
PLoS One. 2016 Apr 11;11(4):e0153327
pubmed: 27065006
Neuropsychopharmacology. 2014 Mar;39(4):955-62
pubmed: 24145852
Biol Psychiatry. 2016 Apr 1;79(7):557-67
pubmed: 26858214
Am J Dis Child. 1989 Oct;143(10):1214-9
pubmed: 2801665
Psychopharmacology (Berl). 2007 Jul;193(1):85-96
pubmed: 17387457
J Neurosci. 2020 Feb 26;40(9):1897-1908
pubmed: 31953372
Addiction. 2002 Sep;97(9):1123-35
pubmed: 12199828
J Exp Anal Behav. 2005 Jan;83(1):67-83
pubmed: 15762381
Curr Psychiatry Rep. 2013 Dec;15(12):419
pubmed: 24234874
J Subst Abuse Treat. 2015 Jan;48(1):96-103
pubmed: 25175495
J Pharm Biomed Anal. 2018 Oct 25;160:119-125
pubmed: 30077950
Neuropsychopharmacology. 2006 Feb;31(2):462-70
pubmed: 16177808
Eur J Pharmacol. 2004 Dec 3;506(1):63-9
pubmed: 15588625
Dialogues Clin Neurosci. 2017 Jun;19(2):181-191
pubmed: 28867942
Behav Brain Res. 2005 Jan 6;156(1):145-52
pubmed: 15474659
Psychopharmacology (Berl). 2009 Apr;203(3):629-40
pubmed: 19048233
Alcohol Clin Exp Res. 2011 Jan;35(1):39-46
pubmed: 20958330
Hippocampus. 2009 Aug;19(8):763-72
pubmed: 19156848
Brain Sci. 2018 Feb 27;8(3):
pubmed: 29495540
Neurosci Lett. 2004 Nov 11;370(2-3):114-7
pubmed: 15488305
Drug Alcohol Depend. 2014 Oct 1;143:141-8
pubmed: 25124305
Psychopharmacology (Berl). 2011 Nov;218(2):443-57
pubmed: 21667074
Neuroscience. 2017 Mar 14;345:274-286
pubmed: 26873002
Pharmacol Biochem Behav. 2009 Oct;93(4):482-90
pubmed: 19576923
Neuropsychopharmacology. 2008 Oct;33(11):2760-71
pubmed: 18172430
Front Psychol. 2010 Dec 14;1:225
pubmed: 21833280
J Am Acad Child Adolesc Psychiatry. 2007 Mar;46(3):408-417
pubmed: 17314727
J Psychopharmacol. 2006 Sep;20(5):611-21
pubmed: 16714325
J Pharmacol Exp Ther. 2007 Sep;322(3):1067-75
pubmed: 17586723
Pharmacol Rep. 2009 Nov-Dec;61(6):1000-7
pubmed: 20081234
BMC Bioinformatics. 2006 Mar 09;7:123
pubmed: 16526949
Pharmacol Biochem Behav. 2006 Sep;85(1):105-13
pubmed: 16934319
Neurobiol Aging. 2016 Sep;45:88-97
pubmed: 27459929
Trends Mol Med. 2015 Jul;21(7):450-60
pubmed: 26070271
Br J Pharmacol. 2020 Jan;177(1):188-203
pubmed: 31478558
Exp Clin Psychopharmacol. 2013 Aug;21(4):287-93
pubmed: 23937597
Hum Psychopharmacol. 2009 Oct;24(7):515-23
pubmed: 19693792
Med Hypotheses. 2013 May;80(5):564-7
pubmed: 23410498
Behav Neurosci. 1995 Feb;109(1):71-8
pubmed: 7734082
Psychol Med. 2009 Oct;39(10):1607-16
pubmed: 19335936
Schizophr Bull. 2015 Mar;41(2):391-9
pubmed: 25031222
Psychopharmacology (Berl). 2019 Sep;236(9):2773-2784
pubmed: 31044291
Neurotox Res. 2009 May;15(4):291-302
pubmed: 19384563
J Neurosci. 2014 Mar 26;34(13):4618-26
pubmed: 24672007
J Psychopharmacol. 2006 Jan;20(1):14-23
pubmed: 16204329
Front Psychiatry. 2014 Sep 29;5:133
pubmed: 25324787
Behav Neurosci. 2016 Feb;130(1):50-61
pubmed: 26653713
JAMA. 2002 Mar 6;287(9):1123-31
pubmed: 11879109
Addict Behav. 2005 May;30(4):815-28
pubmed: 15833584
Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S108-13
pubmed: 18358595
Elife. 2020 Sep 28;9:
pubmed: 32985975
Drug Alcohol Rev. 2003 Dec;22(4):453-60
pubmed: 14660135
J Neurosci. 2014 Mar 5;34(10):3457-66
pubmed: 24599447
Neuropharmacology. 2016 Oct;109:112-120
pubmed: 27256501
Neuropsychopharmacology. 2017 Apr;42(5):989-1000
pubmed: 27582345
Psychopharmacology (Berl). 2006 Aug;187(2):245-59
pubmed: 16752140
Psychopharmacology (Berl). 2009 May;204(1):85-94
pubmed: 19099294
Neuron. 1995 Mar;14(3):477-85
pubmed: 7695894
Psychopharmacology (Berl). 2003 Nov;170(3):301-308
pubmed: 12955302
Neuropsychopharmacology. 2005 Apr;30(4):800-9
pubmed: 15775958
PLoS One. 2017 Jan 6;12(1):e0168897
pubmed: 28060830
Addict Behav. 2010 Nov;35(11):970-6
pubmed: 20621421
Psychopharmacology (Berl). 2015 Jan;232(2):343-53
pubmed: 24998257
Behav Brain Res. 2008 Jun 26;190(1):85-96
pubmed: 18359099
Neuropsychopharmacology. 2004 Aug;29(8):1558-72
pubmed: 15173844
Cannabis Cannabinoid Res. 2019 Dec 06;4(4):240-254
pubmed: 32042924
Exp Clin Psychopharmacol. 2021 Feb;29(1):1-13
pubmed: 32297788
Pharmacol Biochem Behav. 2003 Jun;75(3):577-84
pubmed: 12895675
J Neurosci. 2016 Dec 14;36(50):12537-12548
pubmed: 27807032
Drug Alcohol Depend. 2004 Oct 5;76(1):107-11
pubmed: 15380295
Annu Rev Psychol. 2007;58:145-73
pubmed: 16903808
J Pharmacol Exp Ther. 2005 Jul;314(1):329-37
pubmed: 15831444
J Clin Exp Neuropsychol. 2014;36(4):379-98
pubmed: 24620756
Behav Brain Res. 1998 Aug;94(2):301-10
pubmed: 9722280
Behav Brain Res. 2009 Jul 19;201(1):74-9
pubmed: 19428619
Addict Biol. 2013 Sep;18(5):872-81
pubmed: 22260337
Psychol Addict Behav. 2012 Sep;26(3):496-506
pubmed: 22103843
Neuropsychopharmacology. 2008 Apr;33(5):1113-26
pubmed: 17581536
Eur Neuropsychopharmacol. 2016 Sep;26(9):1378-1389
pubmed: 27461514
Front Aging Neurosci. 2019 Sep 13;11:239
pubmed: 31607897
Neurosci Lett. 2012 Mar 9;511(2):89-94
pubmed: 22306089
Neuropsychopharmacology. 2003 Oct;28(10):1760-9
pubmed: 12888772
Neurobiol Aging. 2017 Dec;60:141-152
pubmed: 28946018
Behav Brain Res. 2006 Jul 15;171(1):116-26
pubmed: 16677723
J Int Neuropsychol Soc. 2007 Sep;13(5):807-20
pubmed: 17697412
Neurobiol Aging. 2013 Sep;34(9):2164-74
pubmed: 23601673
Front Behav Neurosci. 2017 Jul 21;11:137
pubmed: 28785210
BMJ. 2002 Nov 23;325(7374):1195-8
pubmed: 12446533
J Pharmacol Toxicol Methods. 2014 Jul-Aug;70(1):112-9
pubmed: 24956154
Drug Alcohol Rev. 2007 May;26(3):309-19
pubmed: 17454021
Curr Atheroscler Rep. 2017 Jun;19(6):26
pubmed: 28432636
J Clin Exp Neuropsychol. 2012;34(9):962-76
pubmed: 22882144
Neurosci Biobehav Rev. 2014 May;42:116-31
pubmed: 24582908
Neurobiol Learn Mem. 2019 Jan;157:151-162
pubmed: 30521850
Addict Behav. 2013 Nov;38(11):2653-60
pubmed: 23899428
J Int Neuropsychol Soc. 2016 Oct;22(9):944-949
pubmed: 27079834
Science. 1972 Feb 25;175(4024):911-2
pubmed: 5008609
Drug Alcohol Depend. 2012 Feb 1;121(1-2):159-62
pubmed: 21920674
Neuropsychopharmacology. 2005 Oct;30(10):1895-905
pubmed: 15812570
Neuropsychopharmacology. 2007 Mar;32(3):607-15
pubmed: 16823391
Pharmacol Biochem Behav. 2006 Mar;83(3):448-55
pubmed: 16631921
Psychopharmacology (Berl). 2008 Jul;198(4):587-603
pubmed: 18228005
Pharmacol Biochem Behav. 1986 Sep;25(3):577-82
pubmed: 3774823